Hrain Biotechnology is a biotechnology company. The company raised 200 million yuan (about $29 million) in a Series B+ financing, according to the report. The article does not provide details about the company’s products, operations, or financial metrics. It also does not disclose the lead investor(s) or participating backers. Coverage appeared as part of a China-focused funding digest alongside other transactions. Hrain Biotechnology is a Chinese company that researches and develops tumour immunotherapy technologies. Its core focus is on tumour immunotherapy R&D. On Monday it announced it had secured 200 million yuan (US$27.97 million) in a Series B financing. The round was led by Shenzhen Venture Capital, a Chinese state-backed venture capital firm. The announcement did not include details on other investors, use of proceeds, or operating metrics. The article did not disclose prior funding rounds or founding year.

Total raised

$57M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2020